Volume 14 Supplement 17
Power and sample size of two-stage extreme phenotype sequencing design for next generation sequencing studies
© Kang; licensee BioMed Central Ltd. 2013
Published: 22 October 2013
Next-generation sequencing technology is changing the genomic research due to its huge sequencing capacity which is used to identify rare susceptibility variants that affect complex diseases. Because of its high cost, a two-stage extreme phenotype sequencing (TS-EPS) design is an alternative approach  in which the genetic variants are discovered by whole-genome or whole-exome sequencing individuals with extreme phenotypes in stage I and the association variants are detected by sequencing a large number of individuals on the discovered variants in stage II. TS-EPS can efficiently discover more than half of the causal variants using about 0.2% of all individuals  and can therefore have higher power than random sampling given the sample size and effect sizes of the causal variants [2, 3]. Using simulated data for unrelated individuals, we further explore the efficiency of TS-ESP in term of different sample sizes and varying effect sizes.
- Emond MJ, Louie T, Emberson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC, National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project, Lung GO, Gibson RL, Bamshad MJ: Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nature Genet. 2012, 44 (8): 886-889. 10.1038/ng.2344.PubMed CentralView ArticlePubMedGoogle Scholar
- Kang G, Lin D, Hakonarson H, Chen J: Two-stage extreme phenotype sequencing design for discovering and testing common and rare genetic variants: efficiency and power. Hum Hered. 2012, 73 (3): 139-147. 10.1159/000337300.PubMed CentralView ArticlePubMedGoogle Scholar
- Barbett IJ, Lee S, Lin S: Detecting rare variant effects using extreme phenotype sampling in sequencing association studies. Genet Epidemiol. 2013, 37 (2): 142-151. 10.1002/gepi.21699.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.